Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 10/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17609 | 1.00 | ADRB1 (0.36) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL17658 | 0.87 | — | — | |
| SCHEMBL17657 | 0.87 | — | — | |
| SCHEMBL13837225 | 0.79 | SYK (0.45) | ADRB1SYKLOXL2TAS2R14KMT2A | |
| SCHEMBL29607 | 0.79 | ADRB1 (0.38) | ADRB1SYKLOXL2TAS2R14LOX | |
| SCHEMBL17378 | 0.76 | POLB (0.40) | KMT2ANPSR1NPC1GAARAB9A | |
| SCHEMBL17377 | 0.76 | POLB (0.40) | KMT2ANPSR1NPC1GAARAB9A | |
| SCHEMBL18342 | 0.73 | KMO (0.65) | KMT2ANPC1GAARAB9A | |
| SCHEMBL18343 | 0.73 | KMO (0.65) | KMT2ANPC1GAARAB9A | |
| SCHEMBL1578122 | 0.73 | KMO (0.54) | SYKTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2012025460-A1 | OXADIAZOLINONE DERIVATIVES AND USE THEREOF IN PEST CONTROL | BAYER CROPSCIENCE AG (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025460-A1 | OXADIAZOLINONE DERIVATIVES AND USE THEREOF IN PEST CONTROL | BAYER CROPSCIENCE AG (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | ADRB1 2282/4885SYK 4753/4885LOXL2 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.